Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
October 2024—Qiagen has released a new version of its clinical decision support software Qiagen Clinical Insight Interpret. The latest release builds on the advanced artificial intelligence capabilities of QCI Interpret, including AI-derived literature searches and AI-trained phenotype-driven ranking.
September 2024—Agilent Technologies released in June its 2023 environmental, social, and governance report, showcasing sustainable solutions that enable labs worldwide to reduce consumption of nonrenewable resources and minimize waste.
September 2024—Qiagen and Myriad Genetics announced they will develop a globally distributable kit-based test for analyzing homologous recombination deficiency status. This next-generation sequencing test aims to support research into personalized medicine in multiple solid tumor types, including ovarian cancer, and is expected to enhance decentralized testing capacities once a regulated product is developed with pharmaceutical partners. The project builds on the master collaboration agreement that the companies announced in October 2023.
September 2024—Bio-Rad Laboratories has launched its Specialty Immunoassay Plus, a four-level, comprehensive, independent specialty immunoassay quality control designed to monitor the precision of laboratory specialty immunoassay testing procedures. The product is available in barcoded, load-and-go InteliQ and standard vial Liquichek configurations and features clinically relevant analytes such as procalcitonin, interleukin-6, active vitamin B12, anti-TSH receptor, thyroid stimulating immunoglobulins, fructosamine, and others. It also contains optimized vitamin D ranges to support Vitamin D Standardization Program–compliant assays and improved intact parathyroid hormone open-vial stability to minimize QC waste. With the Unity data management software, laboratories can compare results across a large peer group of reporting labs.
September 2024—Roche announced that the FDA has granted emergency use authorization for its Cobas Liat SARS-CoV-2, Influenza A/B, and RSV nucleic acid test for use on the Cobas Liat system. The automated multiplex real-time reverse transcription polymerase chain reaction test is intended for the simultaneous qualitative detection and differentiation of SARS-CoV-2, influenza A and B virus, and respiratory syncytial virus RNA in anterior nasal and nasopharyngeal swab specimens. Definitive results are generated in 20 minutes.
September 2024—Siemens Healthineers has added the NT‑proBNPII assay to its cardiac test menu on the Atellica Solution to help diagnose heart failure. The assay supports timely patient care with a first result available in 10 minutes. The company offers the NT-proBNPII and B-type natriuretic peptide tests on either the Atellica IM or Atellica CI analyzer.
September 2024—BioMérieux announced that its Biofire Spotfire Respiratory/Sore Throat Panel Mini has received FDA special 510(k) clearance and CLIA waiver.
September 2024—Qiagen has launched 35 wet-lab tested digital PCR microbial DNA detection assays for its digital PCR platform QIAcuity. The assays are available on Qiagen’s research platform GeneGlobe and are designed to target a wide range of pathogens, including dengue virus serotypes one to four, mpox clades one and two, and chikungunya, as well as malaria and various sexually transmitted infections and urinary tract infections. The addition of these assays brings the company’s total microbial dPCR assay portfolio to more than 680 targets.
September 2024—BD and Quest Diagnostics announced a worldwide collaboration agreement to develop, manufacture, and commercialize flow-cytometry–based companion diagnostics intended to help select the best treatment for patients with cancer and other diseases. The joint offerings will range from exploratory panel development to the manufacturing and distribution of FDA-approved diagnostic kits.
September 2024—Sakura Finetek Europe announced the launch of the Tissue-Tek xPrint LP laser cassette printer. Features of the laser printer include high-definition barcode printing at 2,500 dpi and a printing speed of up to 2.5 seconds per cassette. It is designed to print on Tissue-Tek Paraform cassettes of any color, without the need for calibration or additional setup. Print quality is robust and resistant to heat, alcohol, xylene, acid, and scratching, as well as other common laboratory conditions. The printer supports a wide range of content, including logos, barcodes, QR codes, data matrices, and text that can be displayed in the Windows system.
